Get the Stockscreener App
90.74
1.75%
1.56
After Hours:
90.72
-0.02
-0.02%
Henry Schein Inc stock is traded at $90.74, with a volume of 1.04M.
It is up +1.75% in the last 24 hours and up +7.51% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$89.18
Open:
$88.945
24h Volume:
1.04M
Relative Volume:
0.74
Market Cap:
$10.11B
Revenue:
$13.38B
Net Income/Loss:
$418.00M
P/E Ratio:
27.40
EPS:
3.3112
Net Cash Flow:
$391.00M
1W Performance:
+1.28%
1M Performance:
+7.51%
6M Performance:
+15.70%
1Y Performance:
+34.43%
1-Day Range:
$88.47
$90.93
1-Week Range:
$87.47
$90.93
52-Week Range:
$61.95
$92.18
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
90.74 | 9.94B | 13.38B | 418.00M | 391.00M | 3.3112 |
MCK
Mckesson Corp
|
878.73 | 105.14B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
314.17 | 63.71B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
234.16 | 55.88B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
1.4695 | 1.19B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein, Inc. (HSIC) Stock Forecasts - finance.yahoo.com
Henry Schein's (NASDAQ:HSIC) Earnings Seem To Be Promising - simplywall.st
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein (HSIC) Q2 2026 Earnings Call Transcript - AOL.com
Should Henry Schein’s (HSIC) Upgraded 2026 Outlook and New Structure Require Action From Investors? - webull.com
Should Value Investors Buy Henry Schein (HSIC) Stock? - finance.yahoo.com
Henry Schein, Inc. (HSIC) Stock Analysis: Navigating a 10.70% Upside Potential with Solid Revenue Growth - directorstalkinterviews.com
Empowered Funds LLC Lowers Holdings in Henry Schein, Inc. $HSIC - MarketBeat
Bank of America Corp DE Boosts Holdings in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Henry Schein (NASDAQ:HSIC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution - Distribution Strategy Group
Henry Schein Inc. stock underperforms Thursday when compared to competitors - MarketWatch
HENRY SCHEIN, INC. : MIZUHO RAISES TARGET PRICE TO $86 FROM $82 - webull.com
HENRY SCHEIN, INC. : BARRINGTON RESEARCH RAISES TARGET PRICE TO $104 FROM $97 - webull.com
Barclays Adjusts Price Target on Henry Schein to $100 From $86 - marketscreener.com
FMR LLC discloses 6.6% Henry Schein (HSIC) stake in Schedule 13G filing - Stock Titan
Should Henry Schein’s Raised 2026 Sales Growth Guidance Require Action From Henry Schein (HSIC) Investors? - finance.yahoo.com
Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run? - finance.yahoo.com
Is Henry Schein (HSIC) Still Cheap After A 37% Run? - finance.yahoo.com
Quantinno Capital Management LP Grows Holdings in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Q2 2026 Earnings: Margin Gains Support Higher Guidance - TradingKey
Henry Schein, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Henry Schein, Inc. Stock 12‑Month Price Target Raised to $91.69, Implies 6% Upside - TradingView
HENRY SCHEIN, INC. : JEFFERIES RAISES TARGET PRICE TO $95 FROM $80 - Bitget
HENRY SCHEIN, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $96 FROM $88 - Bitget
Henry Schein Tops Q2 2026 Profit Forecast With $1.27 EPS - AlphaStreet
Henry Schein, Inc. Raises Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Henry Schein Q2 Earnings Call Highlights - finance.yahoo.com
Henry Schein (Nasdaq: HSIC) lifts Q2 2026 sales to $3.46B and EPS to $0.82 - Stock Titan
Henry Schein Q2 2026 slides: strong growth lifts full-year outlook - Investing.com
Henry Schein stock hits 52-week high at $89.99 - Investing.com
Henry Schein Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Henry Schein (HSIC) Reports Q2 Earnings: What Key Metrics Have to Say - finance.yahoo.com
Henry Schein Q2 2026 Earnings Call: Complete Transcript - Benzinga
Henry Schein, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026 - marketscreener.com
Q2 2026 Henry Schein Inc Earnings Call Transcript - GuruFocus
Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates - finance.yahoo.com
Did Henry Schein Inc (HSIC) Just Beat EPS Estimates with Q2 Earnings? GF Score: 81/100, 2.7% Overvalued - GuruFocus
Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales - finance.yahoo.com
Henry Schein posts Q2 revenue $3.46B, raises FY2026 non-GAAP EPS view to $5.29–$5.39 - TradingView
Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance - finance.yahoo.com
Henry Schein removes 3 longtime execs in leadership shakeup - medtechdive.com
Henry Schein (HSIC) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Henry Schein earnings up next: Leadership changes in focus - Investing.com
Henry Schein, Inc. $HSIC Shares Acquired by Defilade Capital Management L.P. - MarketBeat
List of 35 Acquisitions by Henry Schein (Aug 2026) - Tracxn
Henry Schein (HSIC) Q1 2026 Earnings Call Transcript - Fortune
Henry Schein, Inc. $HSIC Shares Sold by Arrowstreet Capital Limited Partnership - MarketBeat
Michael S. Ettinger and Mark E. Mlotek to Transition to Senior Advisors at Henry Schein - TradingView
Henry Schein stock falls as three executives to exit roles - Investing.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.72%
20.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):